NICE National institute for Clinical hxccllcncc in the SIGN Scottish Intetcollegiate Guidelines Network

Self-assessment questions and answers are available at ht-tp://www. mhpharmacotherapy. com/pp.html.

REFERENCES

1. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975;16:143-161.

2. Annegers JF, Hauswer WA, Eleveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979;20:729-737.

3. Shamansky SL, Glaser GH. Socioeconomic characteristics of childhood seizure disorders in the New Haven area: An epidemiologic study. Epilepsia 1979;20:457-474.

4. Jallon P, Samdja D, Cabre P, et al. Epileptic seizures epilepsy and risk factors: Experiences with an investigation in Martinique. Epimart Group. Rev Neurol (Paris) 1998;154:408-411.

5. Epilepsy Foundation. Driver information by state. ht-tp://www. epilepsyfoundation.org/living/wellness/transportation/drivinglaws.etm. Accessed October 5, 2009.

6. Elger CE, Helmstaedter C, Kurthen M. Chronic epilepsy and cognition. Lancet Neurol 2004;3(11):663-672.

7. Epilepsy Foundation. Education. http://www.epilepsyfoundation.org/answerplace/ Social/education/. Accessed October 5, 2009.

8. Jallon P, Loiseau P, Loiseau J. Newly diagnosed unprovoked epileptic seizures: Presentation at diagnosis in the CAROLE study. Epilepsia 2001;42:464-475.

9. Najm I, Möddel G, Janigro D. Mechanisms of epileptogenesis and experimental models of seizures. In: Wyllie E, ed. The Treatment of Epilepsy. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2006.

10. Jones SW. Basic cellular neurophysiology. In Wyllie E, ed. The Treatment of Epilepsy. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2006.

11. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005;5(1):3-14.

12. Abrous DN, Koehl M, Le Moal M. Adult neurogenesis: From precursors to network and physiology. Physiol 2005;85(2):523-569.

13. Gaitatzis A, Sander JW. The mortality of epilepsy revisited. Epileptic Disord 2004;6:3-13.

14. Panayiotopoulos CP. Idiopathic generalized epilepsies: A review and modern approach. Epilepsia 2005;46(Suppl9):1-6.

15. Wong M. Advances in the pathophysiology of developmental epilepsies. Semin Pe-diatr Neurol 2005; 12:72-87.

16. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.

17. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-399.

18. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: Definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005;46(4):470-472.

19. Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: Report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42:796-803.

20. Smith SJ. EEG in the diagnosis, classification, and management of patients with epilepsy. J Neurol Neurosurg Psychiatry 2005;76(Suppl 2):ii2-ii7.

21. Hauser WA, Rich SS, Annegers JF, et al. Seizure recurrence after a first unprovoked seizure: An extended follow-up. Neurology 1990;40:1163-1170.

22. Lachhwani DK, Wyllie E. Outcome and complications of epilepsy surgery. In Wyllie E, ed. The Treatment of Epilepsy. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2006.

23. National Institute of Neurological Disorders and Stroke. Surgical treatment of epilepsy. Proceedings of a Consensus Conference. March 19-21, 1990. Epilepsy Res 1992;5(Suppl):1-250.

24. Wheless JW. Vagus nerve stimulation therapy. In Wyllie E, ed. The Treatment of Epilepsy. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2006.

25. Nordli DR, DeVivo DC. The ketogenic diet. In Wyllie E, ed. The Treatment of Epilepsy. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2006.

26. Perruca E. An introduction to antiepileptic drugs. Epilepsia 2005;46(Suppl 4):31-37.

27. Privitera MD. Clinical rules for phenytoin dosing. Ann Pharmacother. 1993 0ct;27(10):1169-1173.

28. Scottish Intercollegiate Guidelines Network. Diagnosis and management of epilepsy in adults. http://www.sign.ac.uk/pdf/sign70.pdf. Accessed October 5, 2009.

29. National Institute for Clinical Excellence. The epilepsies: The diagnosis and management of the epilepsies in children and adults in primary and secondary care. http://www.guidance.nice.org.uk/CG20. Accessed October 5, 2009.

30. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new anti-epileptic drugs I: Treatment of new onset epilepsy report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2005;62:1252-1260.

31. French JA, Kanner AM, Bautista J, et.al. Efficacy and tolerability of the new anti-epileptic drugs II: Treatment of refractory epilepsy report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2005;62:1261-1273.

32. Vestergaard P. Epilepsy, osteoporosis and fracture risk—A meta-analysis. Acta Neurol Scand. 2005;112:227-286.

33. Koppel BS, Harden CL, Nikolov BG, Labar DR. An analysis of lifetime fractures in women with epilepsy. Acta Neurol Scand 2005;111(4): 225-228.

34. Harden CL, Goldstein MA. Mood disorders in patients with epilepsy: Epidemiology and management. CNS Drugs 2002;16:291-302.

35. Schmidt D, Loscher W. Uncontrolled epilepsy following discontinuation of anti-epileptic drugs in seizure-free patients: A review of current clinical experience. Acta Neurol Scand 2005;111(5):291-300.

36. Tsur VG, O'Dell C, Shinnar S. Initiation and discontinuation of antiepileptic drugs. In Wyllie E, ed. The Treatment of Epilepsy. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2006.

37. Perucea E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61p):246-255.

38. Bailer M. The pharmacokinetics and interactions of new antiepileptic drugs: An overview. Their Drug Monit 2005;27(6):722-726.

39. Anderson GD. Pharmacogenetic and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004;63(10 Suppl 4):53-58.

40. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 2005;46(Suppl 9):117-124.

41. Foldvary-Schaefer N, Morrel MJ. Epilepsy in women: The biological basis for the female experience. Cleve Clin J Med 2004;71(Suppl 2):S1-S8.

42. Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005;64(11):1874-1878.

31 Status Epilepticus

Gretchen M. Brophy and Eljim P. Tesoro

LEARNING OBJECTIVES

Stop Headache Drug Free

Stop Headache Drug Free

If you are suffering from headaches, you can make the pain stop just by following some basic but little known principles. Take 15 minutes browsing through this guide and you'll find dozens of tips to gain control in the battle against headache pain.

Get My Free Audio Book


Post a comment